title: Cancer of the pyriform fossa: hyperfractionated radiotherapy as a primary treatment modality.
abstract: Carcinoma of the pyriform fossa carries one of the worst prognoses of all head and neck cancers. A prospective trial was set up to study the efficacy of hyperfractionated radiotherapy as a primary treatment modality in the management of these patients. Seventeen patients entered the trial and were followed for up to 3 years. Results for local control, regional control and survival compare favourably with patients treated primarily with surgery with or without radiotherapy. Hyperfractionated radiotherapy offers a logical and standardized approach to the management of this tumour and reduces the significant morbidity associated with the use of surgery as a primary treatment.
authors.affiliation: Department of Otolaryngology Head and Neck Surgery, Mater Hospital, Dublin, Ireland.
authors.forename: B J
authors.initials: BJ
authors.lastname: Conlon
authors.forename: M
authors.initials: M
authors.lastname: Walsh
authors.forename: D
authors.initials: D
authors.lastname: McShane
authors.forename: N
authors.initials: N
authors.lastname: Corcoran
authors.forename: M
authors.initials: M
authors.lastname: Moriarty
authors.forename: J B
authors.initials: JB
authors.lastname: Healy
authors.forename: I
authors.initials: I
authors.lastname: Fraser
authors.forename: T P
authors.initials: TP
authors.lastname: O'Dwyer
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D019583:Dose Fractionation, Radiation; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D015996:Survival Rate